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Introduction {#sec1}
============

Despite advances in early screening strategies and development of treatments tailored to specific molecular subtypes, breast cancer is still a disease associated with significant morbidity and mortality. A major contributing factor is resistance to first-line therapy and disease recurrence coupled with metastatic dissemination. Emerging research suggests that the main phenomenon contributing to this is the presence of "tumor-initiating cells," a small population of cells in the bulk tumor mass that is thought to be responsible for tumor initiation, maintenance, heterogeneity, and drug resistance. Because these cells share many biological traits with normal stem cells, they are often referred to as breast cancer stem cells (BCSCs). BCSCs can asymmetrically divide, producing one stem cell (self-renewal) and one daughter progenitor cell, which is the root of the hierarchy that defines cancer heterogeneity. Importantly, these cells have slow rates of division, high expression of drug efflux pumps, and high capacity for DNA repair ([@bib27]) and are thus relatively drug resistant. Therefore, although BCSCs represent only a small proportion of the bulk tumor, they are of major clinical importance. Given the failure of current treatments, identifying factors that are critical for BCSC function is vital for the development of novel therapies.

In the breast, cancer stem cells (CSCs) are molecularly defined as ESA^+^CD24^low^CD44^+^ ([@bib1], [@bib18]). Transplantation of as few as 1,000 patient-derived ESA^+^CD24^low^CD44^+^ cells enabled reconstitution of a heterogeneous tumor phenotypically resembling the original tumor. Moreover, ESA^+^CD24^low^CD44^+^ cells isolated from xenografts could undergo multiple rounds of serial transfer in mice ([@bib1]). Thus, the ESA^+^CD24^low^CD44^+^ lineage has considerable proliferative and repopulating potential and has been extensively used to isolate cells with increased tumorigenicity, defining the breast tumor-initiating population. This phenomenon can also be recapitulated *in vitro*; culturing of patient-derived or breast cancer cell lines in suspension as mammospheres enriches for tumor-initiating cells that generate *in vivo* tumor growth 1,000 times more potently than monolayer-derived cells ([@bib37]).

Post-translational modification of histone tails leading to changes in chromatin composition and configuration is a principal component of epigenetic-mediated gene expression. Recently, there has been a growing appreciation that histone-modifying enzymes are responsible for promoting gene expression in CSCs that facilitates cellular plasticity between cancer and non-cancer stem cell-like phenotypes ([@bib17], [@bib26], [@bib32]). This is also true in the breast, in which deregulated histone lysine methylation contributes to BCSC function and aggressive disease ([@bib9], [@bib43]). In contrast, very little is understood about the contribution of arginine methylation. Protein arginine methyltransferases (PRMTs) catalyze mono- and dimethylation of the guanidino group of the arginine residue using S-adenosyl methionine (SAM) as a methyl donor. Dimethylation can occur asymmetrically (asymmetric dimethylarginine \[ADMA\]), with two methyl groups placed onto one of the terminal nitrogen atoms of the guanidino group, or symmetrically (symmetric dimethylarginine \[SDMA\]), whereby one methyl group is placed onto each of the terminal nitrogen atoms. Recently PRMT5, the main symmetric arginine dimethyltransferase in mammalian cells, has been increasingly associated with stemness. PRMT5 maintains embryonic stem cell (ESC) pluripotency by upregulating NANOG and OCT4 expression ([@bib42]), promotes somatic cell reprogramming ([@bib23], [@bib33]), and is required for the homeostasis of adult stem cells ([@bib30], [@bib46]). Notably, PRMT5 can drive or repress gene expression according to the modified histone residue; histone H3R2me2s drives H3K4me3 and gene expression, while methylation of H2AR3, H4R3, and H4R8 represses gene activation ([@bib15], [@bib31]). Given the parallels between normal stem cell function, somatic cell reprogramming, and CSCs, these findings imply that PRMT5 may be an important regulator of CSCs. Indeed, PRMT5 has been shown to contribute to leukemic and glioblastoma stem cell function ([@bib3], [@bib29]). Regarding the breast, very few studies have addressed the potential pro-tumorigenic role of PRMT5, despite high PRMT5 expression being associated with breast cancer progression, aggressive disease, and poor prognosis ([@bib10], [@bib38], [@bib45]). Using a systematic *in vitro* and *in vivo* approach to analyze the contribution of PRMT5 to BCSC function, we found that PRMT5 depletion in established estrogen receptor (ER)^+^ xenografts not only reduced tumor growth but substantially reduced the proportion of BCSCs after serial transplantation. Significantly, treatment of BCSCs isolated from patient-derived tumors with a pre-clinical PRMT5 small-molecule inhibitor substantially reduced tumor-initiating potential. Our results thus demonstrate the importance of PRMT5-mediated arginine methylation for BCSC function and tumor initiation and imply that drug targeting of this pathway could have significant patient benefit by eradicating the cell population responsible for drug resistance and recurrence.

Results {#sec2}
=======

PRMT5, but Not PRMT1, Is Functionally Required for *In Vitro* BCSC Function in ER^+^ Breast Cancers {#sec2.1}
---------------------------------------------------------------------------------------------------

PRMT1 and PRMT5 have been increasingly linked to stem cell function in normal and cancer cells ([@bib3], [@bib5], [@bib29], [@bib30], [@bib46]) and breast cancer pathogenesis ([@bib2], [@bib10], [@bib22], [@bib38], [@bib45]). Whilst depletion of PRMT5 reduces the proliferation of bulk MCF7 breast cancer cells ([Figure S1](#mmc1){ref-type="supplementary-material"}A; [@bib39]), no study has yet examined whether PRMT1 and PRMT5 also regulate the BCSC population. To address this, we exploited the fact that breast cancer cell lines possess a small population of cells that molecularly and functionally behave as cancer stem cells ([@bib26], [@bib37]). Two approaches were used to isolate this population: flow cytometry gating on ESA^+^CD24^low^CD44^+^ ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and the isolation of viable MCF7 cells after 16 hr suspension culture on poly-HEMA-coated plates to prevent cell attachment ([Figure S1](#mmc1){ref-type="supplementary-material"}C). These anoikis-resistant (AR) cells are significantly enriched in stem cell markers compared with their monolayer counterpart and have tumor-initiating capacities ([@bib26]). Although PRMT1 levels remained the same, PRMT5 expression was significantly elevated within the AR or BCSC population ([Figures 1](#fig1){ref-type="fig"}A and 1B). To investigate the significance of this, we generated two PRMT1 and PRMT5-knockdown MCF7 cell lines each expressing distinct short hairpin RNA (shRNA) sequences (shPRMT1\[1\] and shPRMT1\[2\]; shPRMT5\[1\] and shPRMT5\[2\]; [Figure 1](#fig1){ref-type="fig"}C) and analyzed their ability to form mammospheres, a measure of the number and proliferative potential of tumor-initiating cells *in vitro* ([@bib37]). Depletion of either PRMT1 or PRMT5 reduced primary mammosphere formation, indicative of either reduced stem cell/progenitor proliferation or a reduction in the number of tumor-initiating cells, but only depletion of PRMT5 led to a further reduction in secondary mammospheres, suggesting self-renewal defects ([Figure 1](#fig1){ref-type="fig"}C). Thus, it appears that although both PRMT1 and PRMT5 are required for BCSC proliferation and production of progenitor cells, only PRMT5 is required for BCSC self-renewal. To validate these findings, we repeated these experiments in a second ER^+^ breast cancer cell line, T47D ([Figure 1](#fig1){ref-type="fig"}D), and analyzed stem cell numbers by ALDEFLUOR staining, an alternative marker of BCSCs ([@bib21]). As depletion of PRMT5 also reduced the proportion of ALDEFLUOR^+^ T47D cells ([Figure 1](#fig1){ref-type="fig"}E), our data strongly imply that PRMT5 is required for maintaining BCSC function *in vitro*.Figure 1PRMT5 Is Preferentially Expressed in BCSC-Enriched Cell Populations and Is Required for Self-Renewal of ER^+^ Breast Cancer Cells(A and B) Immunoblot of PRMT5 and PRMT1 levels in (A) anoikis-resistant and (B) ESA^+^CD24^low^CD44^+^ BCSC-enriched populations of MCF7 cells, quantified below.(C) Immunoblot of MCF7 cells expressing a non-targeting shRNA or two independent shRNAs targeting either PRMT1 or PRMT5 (shCTRL, shPRMT1\[1\], shPRMT1\[2\], shPRMT5\[1\] and shPRMT5\[2\]) (top). Mammosphere assay of cells after PRMT1 or PRMT5 depletion (bottom).(D) Mammosphere assay of T47D ER^+^ breast cancer cells expressing shCTRL, shPRMT5(1), or shPRMT5(2). PRMT5 depletion is shown (above). MFU, mammosphere-forming unit.(E) ALDEFLUOR assay of T47D shCTRL, shPRMT5(1), or shPRMT5(2). Percentage ALDEFLUOR^+^ cells is quantified (right).(F) Immunoblot of PRMT5, MEP50, and pan-symmetric dimethylarginine (SDMA) in MCF7 cells engineered to express wild-type or enzymatically inactive PRMT5 (PRMT5-WT or PRMT5 G367A/R368A) and/or MEP50.(G) Mammosphere assay of cells overexpressing PRMT5 and/or MEP50.All data are mean ± SEM, n ≥ 3.

Amplification and overexpression of PRMT5 in breast cancer is associated with reduced patient survival rates ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E) ([@bib7], [@bib20], [@bib25]). Since chromatin-modifying enzymes are known to regulate cellular events that can lead to the conversion of non-CSCs toward a CSC-like phenotype and the expansion of the BCSC pool ([@bib9], [@bib41]), we next asked whether overexpression of active PRMT5 by co-expressing PRMT5 and its essential cofactor MEP50 was sufficient to promote a BCSC phenotype. As expected, co-expression of PRMT5 requires MEP50 for elevated symmetric dimethylation levels ([Figures 1](#fig1){ref-type="fig"}F, [S1](#mmc1){ref-type="supplementary-material"}F, and S1G). Accordingly, overexpression of PRMT5 alone had no significant effect on primary mammosphere numbers, whereas co-expression of PRMT5 and MEP50 significantly increased both primary and secondary mammosphere numbers ([Figure 1](#fig1){ref-type="fig"}G). Interestingly, co-overexpression of catalytically inactive PRMT5 (PRMT5-G367A/R368A) ([@bib36]) with MEP50 failed to stimulate BCSC activity ([Figures 1](#fig1){ref-type="fig"}F and 1G). These findings therefore imply that PRMT5 drives BCSC proliferation and self-renewal via the methylation of target substrates.

PRMT5 Is Required for *In Vivo* BCSC Maintenance {#sec2.2}
------------------------------------------------

The gold-standard *in vivo* assay to determine tumor-initiating capacity of putative BCSCs is limiting dilution analysis. Here, groups of NSG (NOD/Scid/IL-2Rγnull) mice were subcutaneously injected with five different dilutions (5 × 10^6^ to 5 × 10^4^) of unsorted cells and monitored for tumor growth, the premise being that the more tumor-initiating cells present within the bulk tumor cell population, the fewer cells required to generate a tumor ([Figure 2](#fig2){ref-type="fig"}A). After 20 days, control animals from the 5 × 10^6^ cell group reached license limit, and all mice were scored for the presence of tumors \>0.1 cm^3^ as evidence of tumor initiation. Depletion of PRMT5 clearly showed a reduction in the potential to form tumors at all cell numbers injected, becoming more evident with small cell numbers. For example, whereas 4 of 7 mice (57%) injected with 5 × 10^4^ shCTRL cells developed tumors, only 1 of 11 mice (9.1%) injected with the same number of shPRMT5 cells did so. Strikingly, using L-Calc (Stem Cell Technologies) to calculate stem cell frequency, we show that depletion of PRMT5 reduced cancer stem cell numbers from 1:187,878 to 1:1,042,530, a 5.5-fold reduction ([Figure 2](#fig2){ref-type="fig"}B). In order to determine the effects of PRMT5 depletion on BCSC and tumor biology, mice in each group were aged and sacrificed when control animals reached license limit. Tumors were excised and analyzed for stem cell function by mammosphere assay. Importantly, the reduction in stem cell frequency was reflected *ex vivo*, as PRMT5-depleted cells from excised tumors displayed reduced proliferation and self-renewal characteristics ([Figure 2](#fig2){ref-type="fig"}C). Consistent with a reduction in stem cells, we observed that PRMT5-depleted tumors were less proliferative, as indicated by differences in final tumor weight, BrdU incorporation, and tumor growth rate ([Figures 2](#fig2){ref-type="fig"}D--2F and [S2](#mmc1){ref-type="supplementary-material"}). Conversely, overexpression of active PRMT5 in limiting dilution xenografts increased stem cell numbers by 5.91-fold ([Figures 2](#fig2){ref-type="fig"}G, 2H, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B), which was reflected *ex vivo* by mammosphere assay ([Figure 2](#fig2){ref-type="fig"}H). Together, this *in vivo* analysis clearly shows that elevated levels of active PRMT5 are sufficient for BCSC activity.Figure 2PRMT5 Is Required for Maintenance of Stem Cells *In Vivo*(A) Schematic of limiting dilution assay. MCF7 shCTRL or shPRMT5 cells were injected into NSG mice in a limiting dilution assay. PRMT5 levels of cells injected were assessed by immunoblotting prior to the experiment (top).(B) Stem cell frequencies of MCF7 shCTRL and shPRMT5 cells were determined using L-Calc software. Upper table shows number of tumors with a positive response (response = tumor \> 0.1 cm^3^ at 20 days post-injection)/total number of tumors and is depicted in the pie chart diagram below. Lower table shows stem cell frequency ± 95% confidence intervals.(C) Mammosphere (MS) assays of tumor-derived cells from the indicated cell number injected. For 5 × 10^6^, error is mean ± range; for 5 × 10^5^ and 5 × 10^4^, error is mean ± SEM.(D) Dot density plot of final tumor weight. The bar represents mean. Table below shows the average tumor weight ± SEM.(E) Representative images of BrdU-stained tumor sections from shCTRL or shPRMT5-expressing cells. The scale bar represents 50 μm.(F) Immunoblot of PRMT5 in tumors derived from 5 × 10^5^ shCTRL or shPRMT5-expressing cells (above). Images of resected tumors (below).(G) Stem cell frequencies of MCF7 CTRL or PRMT5/MEP50 cells were determined using L-Calc software. Upper table shows number of tumors with a positive response (response = tumor \> 0.1 cm^3^ at 39 days post-injection)/total number of tumors and is depicted below. Lower table shows stem cell frequency ± 95% confidence intervals.(H) Mammosphere assay of cells isolated from CTRL and PRMT5/MEP50 tumors.Unless otherwise stated, all data are mean ± SEM, n ≥ 3.

Although our limiting dilution analysis demonstrates an important role for PRMT5 in regulating BCSCs, PRMT5 is also known to promote the proliferation of bulk breast cancer cells ([Figure S1](#mmc1){ref-type="supplementary-material"}A; [@bib39]). In line with this, depletion of PRMT5 reduces both the *in vitro* and *in vivo* proliferation of isolated BCSCs and the differentiated population ([Figures S3](#mmc1){ref-type="supplementary-material"}C--S3H). Importantly, and in agreement with our limiting dilution analysis using bulk cell population ([Figures 2](#fig2){ref-type="fig"}B and 2G), depletion of PRMT5 affected the tumor-initiating capacity of only ESA^+^CD24^low^CD44^+^ BCSCs ([Figure S3](#mmc1){ref-type="supplementary-material"}E), not the differentiated population ([Figure S3](#mmc1){ref-type="supplementary-material"}G). Taken together, these results imply that PRMT5 has multiple roles in breast cancer growth, regulating both tumor-initiating and more differentiated cells, and that drug targeting of PRMT5 could potentially affect the survival of both cell populations.

To investigate the impact of PRMT5 depletion on tumor biology, we performed histological analysis of excised tumors in collaboration with a breast cancer pathologist and scored for pathological features currently used in patient diagnosis. We observed that PRMT5-depleted tumors displayed reduced cellularity, increased fibrosis, and tubule formation, consistent with a less aggressive phenotype ([Figures 3](#fig3){ref-type="fig"}A, 3B, and [S4](#mmc1){ref-type="supplementary-material"}A). Control tumors often exhibited high cellularity and large areas of clear cell differentiation ([Figure 3](#fig3){ref-type="fig"}E), a phenotype of a particularly aggressive breast cancer subtype. Areas of necrosis, another feature of large, rapidly growing tumors, were also observed in shCTRL tumors ([Figures 3](#fig3){ref-type="fig"}C and 3D). These features were rarely exhibited in PRMT5-depleted tumors, correlating with their small size. Interestingly, depletion of PRMT5 in AR or ESA^+^CD24^low^CD44^+^ populations did not alter cell cycle or promote apoptosis ([Figures 3](#fig3){ref-type="fig"}F and 3G). Hence, given that PRMT5-depleted tumors appear more differentiated with a less aggressive pathology, our findings are consistent with PRMT5 suppressing differentiation and thus facilitating the maintenance of BCSC identity.Figure 3Depletion of PRMT5 Reduces Tumor Aggressiveness but Does Not Affect Cell Cycle or Apoptosis(A--E) Tumors were assessed for pathological features and are depicted in pie charts as indicated. Representative images of (A and B) cellularity, fibrosis, tubule formation; (C and D) necrosis; and (E) clear cells. F, fibrous tissue; N, necrotic areas; T, tubule. The scale bar represents 100 μm.(F) Cell cycle profiles of shCTRL or shPRMT5 AR cells.(G) Annexin-FITC^+^ cells in ESA^+^CD24^low^CD44^+^ cells, quantified (right). NS, not significant.All data are mean ± SEM, n ≥ 3.

PRMT5 Is Required for BCSC Function in Established Tumors {#sec2.3}
---------------------------------------------------------

Recently, PRMT5 has become an attractive therapeutic target for the treatment of leukemia and lymphoma, with pre-clinical PRMT5-specific inhibitors displaying impressive *in vivo* efficacy in murine models of mantle cell lymphoma and chronic myelogenous leukemia (CML) ([@bib8], [@bib29]). However, these studies did not address the effect of suppressing or inhibiting PRMT5 on tumor growth in an organism that had already presented with disease, a critical question if PRMT5 inhibitors are to be a viable therapeutic option. We therefore engineered MCF7 cells to express a doxycycline (dox)-regulated PRMT5 silencing construct (Tet-ON-shPRMT5) in combination with constitutive expression of the luciferase gene enabling *in vivo* imaging of tumor growth ([Figures 4](#fig4){ref-type="fig"}A and 4B). After subcutaneous injection, tumors were allowed to grow to a palpable size ([Figure S4](#mmc1){ref-type="supplementary-material"}B) and *in vivo* PRMT5 depletion induced by feeding mice dox-supplemented chow ([Figures 4](#fig4){ref-type="fig"}A and 4B). Tumors derived from Luc-Tet-ON-shCTRL cells continued to grow for the duration of the experiment. In contrast, *in vivo* depletion of PRMT5 substantially slowed tumor growth and in some cases caused regression ([Figures 4](#fig4){ref-type="fig"}C and 4D). Accordingly, Luc-Tet-ON-shPRMT5-derived tumors were considerably smaller than control tumors ([Figures 4](#fig4){ref-type="fig"}E and 4F).Figure 4*In Vivo* Depletion of PRMT5 Reduces Tumor Growth(A) Immunoblot of PRMT5 in MCF7 Luc-Tet-ON-shCTRL and shPRMT5 cells ± 1 μg/mL doxycycline (dox) for 5 days.(B) Schematic of study. Mice were injected with MCF7 cells expressing dox-inducible Luc-Tet-ON-shCTRL or shPRMT5. Tumors were allowed to develop, and when palpable, mice were fed dox-supplemented chow to induce shRNA expression. Tumor growth was monitored by IVIS and caliper measurements.(C) IVIS images of mice injected with Luc-Tet-ON shCTRL or shPRMT5 cells at times shown. Images were taken using the same exposure settings. Exposure time = 1 s. (In some cases, mice were reimaged after unsuccessful luciferin injection. Images have been cropped accordingly \[dotted white lines\].)(D) Growth of tumors before and after dox-supplemented diet.(E) Image of resected tumors from Luc-Tet-ON shCTRL or shPRMT5 cells.(F) Dot density plot of final tumor weight. The bar represents the mean.All data are mean ± SEM, n ≥ 3.

Although these results suggest that PRMT5 is required to sustain the growth of an established carcinoma, we wanted to determine if this was through the maintenance of the BCSC population. We therefore serially transplanted cells derived from Luc-Tet-ON-shCTRL and shPRMT5 tumors and conducted limiting dilution analysis. Excised tumors were dissociated into single cells, and five groups of NSG mice were subcutaneously injected with 1 × 10^5^ to 1 × 10^3^ tumor-derived cells ([Figure 5](#fig5){ref-type="fig"}A). PRMT5 silencing in the transplanted cells was validated by immunoblotting, and tumors were allowed to develop for 40 days. As expected, mice injected with larger numbers of cells were more likely to develop tumors than those injected with small cell numbers ([Figure 5](#fig5){ref-type="fig"}C); however, irrespective of cell number, PRMT5-depleted serially transplanted tumors grew at a much slower rate ([Figures 5](#fig5){ref-type="fig"}B and 5D). Furthermore, examination of the 1 × 10^3^ cell group clearly demonstrated that whereas serially transplanted Luc-Tet-ON-shCTRL-derived tumors steadily outgrew, Luc-Tet-ON-shPRMT5-derived tumors cells failed to generate any growths ([Figure S4](#mmc1){ref-type="supplementary-material"}C). These findings strongly indicate that *in vivo* depletion of PRMT5 alters the functional capacity of tumor-initiating cells. Indeed, by scoring the number of mice that presented with tumors \>0.1 cm^3^ at time of collection (all mice irrespective of group were collected at the same time), Luc-Tet-ON-shPRMT5-derived, serially transplanted tumors displayed a 12-fold reduction in stem cell frequency, from 1:3,555 to 1:43,135, after *in vivo* PRMT5 depletion ([Figure 5](#fig5){ref-type="fig"}C). Consistent with a reduced tumorigenic capacity, PRMT5-depleted xenografts were of a lower cellularity, displayed frequent tubule formation, and were sometimes highly fibrotic, resulting in a greater proportion of tumors with a lower histological grade ([Figures 5](#fig5){ref-type="fig"}E, [S4](#mmc1){ref-type="supplementary-material"}D, and S4E). In support, mammosphere analysis of resected and dissociated tumors demonstrated that PRMT5 depletion reduced mammosphere-forming capacity *ex vivo* ([Figure 5](#fig5){ref-type="fig"}F). Taken together, our data are highly suggestive that depletion of PRMT5 in established carcinomas reduces tumor propagation by restricting the number of BCSCs.Figure 5*In Vivo* Depletion of PRMT5 Reduces Stem Cell Frequency(A) Schematic of study. Following *in vivo* depletion of PRMT5, MCF7 Luc-Tet-ON-shCTRL and shPRMT5 tumors were harvested. Immunoblot of PRMT5 in resected tumors (C1-3 and P1-3 denote Luc-Tet-ON-shCTRL and PRMT5 tumors, respectively) that were dissociated into single cells and injected into NSG mice in a limiting dilution assay. Tumor growth was monitored by IVIS and caliper measurements.(B) Tumor growth in mice injected with 1 × 10^5^ cells (Gp1; solid line) or 5 × 10^3^ cells (Gp5; dashed line).(C) Stem cell frequencies of Luc-Tet-ON shCTRL and shPRMT5 cells were determined using L-Calc software. Upper table shows number of tumors with a positive response (response = tumor \> 0.1 cm^3^)/total number of tumors and is depicted below. Lower table shows stem cell frequency ± 95% confidence intervals.(D) IVIS images of mice injected with 1 × 10^5^ tumor-derived Luc-Tet-ON shCTRL or shPRMT5 cells at the specified time points.(E) Tumors were assessed for pathological features and depicted in pie charts as indicated. Representative images (right) of pathological features. F, fibrous tissue; T, tubule. The scale bar represents 100 μm.(F) Dot density plot of mammosphere formation of tumor-derived cells. The bar represents the mean. Red, pool of two tumors; blue, pool of three tumors.All data are mean ± SEM, n ≥ 3.

PRMT5 Epigenetically Regulates *FOXP1* Expression {#sec2.4}
-------------------------------------------------

Because PRMT5 is an established regulator of gene expression ([@bib31], [@bib47]), we hypothesized that one mechanism by which PRMT5 could be regulating BCSC function was through transcriptional control. To investigate this, we isolated three replicates of the ESA^+^CD24^low^CD44^+^ populations from MCF7-shCTRL and shPRMT5 cells and conducted RNA sequencing (RNA-seq) to identify differences in gene expression. Depletion of PRMT5 resulted in 214 significantly differentially regulated genes, of which 136 were upregulated and 78 downregulated ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5C). KEGG pathway analysis of enriched genes suppressed by PRMT5 (i.e., those that were upregulated after shRNA depletion) identified cancer pathways and signaling pathways (including cGMP-PGK, PI3K-AKT, ErbB, and FoxO pathways) ([Figure S5](#mmc1){ref-type="supplementary-material"}D), while metabolic genes are predominantly induced by PRMT5 (*ALDOC*, *HK2*, *TSTA3*, and *ALDH3A1*; [Figure S5](#mmc1){ref-type="supplementary-material"}E). Changes in expression of classic stem cell genes such as *OCT4* or *NANOG* were not detected by RNA-seq. However, closer examination by qPCR analysis of AR cells reconstituted with wild-type PRMT5 did imply that they were PRMT5 regulated ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Interestingly, Wnt/β-catenin genes, reported as PRMT5 targets in leukemic stem cells ([@bib29], [@bib42]), could not be validated by qPCR (*Wnt5A*, *PRICKLE2*), implying that the mechanisms by which PRMT5 regulates stem cells in breast cancer and leukemia are different.

Surprisingly, none of our top differentially expressed validated genes appeared to have a close correlation with breast cancer pathogenesis ([Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C), and although *CDKN1A* was validated as a PRMT5-repressed gene ([Figure S6](#mmc1){ref-type="supplementary-material"}B), the functional significance of this is unclear given that the cell cycle profiles of shCTRL or PRMT5-depleted AR cells were indistinguishable ([Figure 3](#fig3){ref-type="fig"}F). We thus decided to focus our investigations on FOXP1, a winged helix/forkhead transcription factor that has been associated with normal and cancer stem cell function ([@bib12], [@bib19], [@bib34]). Intriguingly, FOXP1 is generally considered a tumor suppressor in the breast because high levels correlate with better prognosis, despite the finding that it promotes proliferation and migration of breast cancer cell lines ([@bib35], [@bib40], [@bib44]). Because of this apparent contradiction and link with stem cell biology ([@bib12], [@bib19]), we decided to investigate the relationship between PRMT5, FOXP1, and BCSC function in more detail.

Similar to PRMT5, FOXP1 levels were significantly elevated in AR cells ([Figure 6](#fig6){ref-type="fig"}A). Importantly, expression was PRMT5 dependent, as depletion of PRMT5 decreased both protein (full-length 75 kDa FOXP1 isoform) and mRNA transcripts in AR and ESA^+^CD24^low^CD44^+^ cells ([Figures 6](#fig6){ref-type="fig"}B--6D). Moreover, *FOXP1* expression was dependent on the catalytic activity of PRMT5 as reconstitution of PRMT5-depleted cells with ectopic wild-type but not catalytically inactive PRMT5 increased *FOXP1* transcripts ([Figure 6](#fig6){ref-type="fig"}C). We next wanted to determine if PRMT5 was directly regulating *FOXP1* expression. Using total cell population, we used chromatin immunoprecipitation (ChIP) coupled to promoter tiling to demonstrate an enrichment of PRMT5 at the *FOXP1* promoter. In comparison, PRMT5 was not recruited to the *MYOD1* promoter, a muscle-specific gene regulated by PRMT5 but not expressed in MCF7 cells ([@bib14]) ([Figures 6](#fig6){ref-type="fig"}E and [S7](#mmc1){ref-type="supplementary-material"}A and S7B). Importantly, PRMT5 depletion significantly reduced PRMT5 promoter occupancy ([Figures 6](#fig6){ref-type="fig"}E and [S7](#mmc1){ref-type="supplementary-material"}B), confirming that PRMT5 is truly recruited to the *FOXP1* promoter and validating specificity of our PRMT5 ChIP antibody. One mechanism by which PRMT5 promotes gene expression is through the methylation of H3R2 (H3R2me2s), which is recognized by WDR5, enabling the recruitment of the SET1/MLL complex and histone H3K4 trimethylation (H3K4me3) ([@bib31]). Consistent with this chain of events, H3R2me2s, SET1, and H3K4me3 were all enriched at the *FOXP1* promoter in a PRMT5-dependent manner ([Figures 6](#fig6){ref-type="fig"}F--6H and [S7](#mmc1){ref-type="supplementary-material"}C--S7E). Crucially, this observation was also true in the tumor-initiating population, as treatment of AR cells with the PRMT5 inhibitor GSK591 ([@bib16]) substantially reduced *FOXP1* promoter H3K4me3 levels ([Figure 6](#fig6){ref-type="fig"}I), and treatment of primary mammospheres with the WDR5 antagonist OICR-9429 ([@bib24]) reduced BCSC proliferation in a dose-dependent manner ([Figure S7](#mmc1){ref-type="supplementary-material"}G). Even though global levels of H3R2me2s were not altered by PRMT5 depletion ([Figure S7](#mmc1){ref-type="supplementary-material"}H), our findings are highly supportive that PRMT5 is directly recruited to the *FOXP1* promoter, facilitating H3K4me3 and gene expression via H3R2me2s.Figure 6PRMT5 Epigenetically Regulates FOXP1 Expression(A) FOXP1 (75 kDa isoform) and PRMT5 protein levels were assessed in the AR population in MCF7 cells and quantified below.(B) Immunoblot of FOXP1 levels in AR cells after PRMT5 depletion.(C) *FOXP1* expression was assessed by qPCR in AR cells isolated from MCF7 shCTRL, shPRMT5, and shPRMT5 + PRMT5 (WT)/PRMT5 G367A/R368A (MD) cells. Immunoblot of PRMT5 (below).(D) *PRMT5* and *FOXP1* transcript levels were assessed in MCF7 or MCF10A cells after PRMT5 depletion.(E--H) Enrichment of (E) PRMT5, (F) H3R2me2s, (G) SET1, and (H) H3K4me3 or rabbit IgG at the *FOXP1* promoter was assessed by ChIP-qPCR.(I) H3K4me3 enrichment at the *FOXP1* promoter in AR cells ± GSK591.(J and K) Growth curve of MCF7 cells after (J) FOXP1 depletion or (K) FOXP1 overexpression.(L) Average weight of shCTRL or shFOXP1 tumors. Images of resected tumors (below).(M) Mammosphere assay of FOXP1-depleted cells overexpressing PRMT5 and MEP50. Immunoblot of FOXP1 (right).All data are mean ± SEM, n ≥ 3.

Given that FOXP1 has been proposed to function as a tumor suppressor in the breast, we wanted to determine the effect of FOXP1 on MCF7 growth. In support of a pro-tumorigenic role, FOXP1 depletion in MCF7 cells results in growth suppression, whereas overexpression enhances growth ([Figures 6](#fig6){ref-type="fig"}J and 6K). More significantly, depletion of FOXP1 in xenografts significantly reduced tumor growth ([Figures 6](#fig6){ref-type="fig"}L and [S7](#mmc1){ref-type="supplementary-material"}F). Indeed, transcript levels of *FOXP1* are elevated \>11-fold in MCF7 cells compared with immortalized but non-transformed mammary epithelial MCF10A cells ([Figure 6](#fig6){ref-type="fig"}D). Next, we wanted to determine if PRMT5-mediated upregulation of FOXP1 is required for BCSC function. Interestingly, FOXP1 depletion in MCF7 cells expressing endogenous levels of PRMT5/MEP50 reduced primary mammosphere numbers but did not significantly affect secondary mammospheres ([Figures 6](#fig6){ref-type="fig"}M and [7](#fig7){ref-type="fig"}B), implying that under these conditions, FOXP1 regulates BCSC numbers and proliferation rather than self-renewal. In contrast, depletion of FOXP1 on the background of ectopically expressed PRMT5 and MEP50 completely abrogated the effects of PRMT5 and MEP50 overexpression on both BCSC numbers and proliferation and self-renewal ([Figure 6](#fig6){ref-type="fig"}M), implying that the effects of hyperactive PRMT5 on BCSC proliferation and self-renewal are mediated through FOXP1. These findings therefore suggest that a threshold level of FOXP1 expression, presumably via PRMT5-mediated epigenetic regulation, is required for self-renewal or that high levels of an unknown FOXP1 cofactor that drives self-renewal gene expression is present only under certain PRMT5 conditions.Figure 7Inhibition of PRMT5 Reduces Self-Renewal in Cancer Cells and Sensitizes Mammospheres to 4-OHT Treatment(A) Inhibition of PRMT5 activity using GSK591 was shown by immunoblotting for pan-symmetric dimethylarginine (SDMA). SmD3, a known target of PRMT5 was used as a loading control.(B) Mammosphere assay of MCF7 shCTRL or shFOXP1, SUM159 (triple negative), and MCF10A cells treated with 5 μM GSK591 or DMSO (vehicle control).(C) Mammosphere assay of MCF7 cells overexpressing FOXP1 ± 5μM GSK591.(D) Primary mammosphere assay of MCF7 shCTRL or shPRMT5 cells ± 2.5 μM 4-OHT.(E) Primary mammospheres from (D) were dissociated and replated. Secondary mammospheres were scored.(F) Schematic of experiment. Patient-derived tumors were dissociated into single cells. Mammosphere assay of tumor-derived cells ± 5μM GSK591 (right). Representative images of mammospheres are shown.All data are mean ± SEM, n ≥ 3.

Pharmacological Inhibition of PRMT5 Reduces BCSC Numbers *In Vitro* {#sec2.5}
-------------------------------------------------------------------

Because we demonstrated that the catalytic activity of PRMT5 was required for driving BCSC function and FOXP1 expression ([Figures 1](#fig1){ref-type="fig"}G and [6](#fig6){ref-type="fig"}C), we wanted to determine whether a small-molecule inhibitor targeting PRMT5 could affect BCSC function. We therefore treated MCF7 cells with the validated PRMT5 inhibitor GSK3203591 (EPZ015866; herein referred to as GSK591) ([Figure 7](#fig7){ref-type="fig"}A; [@bib16]). Similar to PRMT5 depletion, inhibition of PRMT5 significantly suppressed MCF7-derived BCSC proliferation and self-renewal and the number of ALDEFLUOR^+^ T47D cells ([Figures 7](#fig7){ref-type="fig"}B and [S7](#mmc1){ref-type="supplementary-material"}I), while overexpression of FOXP1 was able to rescue the BCSC proliferative defect induced by GSK591 ([Figure 7](#fig7){ref-type="fig"}C). Our data thus imply that drug targeting PRMT5 reduces the activity of BCSCs, but given that depletion of FOXP1 and GSK591 was not epistatic in reducing primary and secondary mammospheres ([Figure 7](#fig7){ref-type="fig"}B), FOXP1 is important but not sufficient for all PRMT5-dependent events in BCSCs.

PRMT5 has been reported as a critical component of normal stem cell function ([@bib11], [@bib30]), hence one potential limitation of PRMT5-directed therapies for breast cancer is the suppression of normal mammary stem cell function. Interestingly, although knockdown and inhibition of PRMT5 reduces the number of primary mammospheres of MCF10A cells, self-renewal was unaffected ([Figures 7](#fig7){ref-type="fig"}B, [S7](#mmc1){ref-type="supplementary-material"}I, and S7J). In support, stem cell numbers, as determined by ALDEFLUOR staining was unaffected by GSK591 ([Figure S7](#mmc1){ref-type="supplementary-material"}I). Moreover, this lack of effect of PRMT5 deletion or inhibition on MCF10A self-renewal was not due to receptor status, as treatment of the triple-negative breast cancer cells SUM159 with GSK591 phenocopies that of MCF7 cells, reducing both BCSC proliferation and self-renewal ([Figure 7](#fig7){ref-type="fig"}B). Hence, it appears that PRMT5 activity specifically affects self-renewal of cancer rather than normal mammary stem cells.

We next wanted to evaluate the ability of PRMT5 depletion to synergize with conventional chemotherapy for ER^+^ tumors. Although PRMT5 depletion did not alter the ability of 4-hydroxytamoxifen (4-OHT), the active metabolite of tamoxifen, to suppress primary mammosphere numbers ([Figure 7](#fig7){ref-type="fig"}D), secondary mammosphere formation was markedly reduced ([Figure 7](#fig7){ref-type="fig"}E). Thus, PRMT5 inhibitors in combination with 4-OHT appear to synergistically suppress BCSC self-renewal.

To correlate our cell culture findings with therapeutic potential, we isolated cancer cells from freshly resected ER^+^ patient-derived tumors from a cohort that had not undergone neo-adjuvant chemotherapy and conducted mammosphere analysis in the presence of GSK591. Continuous treatment of patient-derived BCSCs with GSK591 markedly suppressed mammosphere formation, indicative that inhibition of PRMT5 is effectively depleting primary-derived BCSCs ([Figure 7](#fig7){ref-type="fig"}F). Taken together, our results strongly imply that therapeutic targeting of PRMT5 could be an effective way of eradicating the cancer stem cell compartment.

Discussion {#sec3}
==========

PRMT5 has been increasingly associated with maintaining normal cell and leukemic cell "stemness" ([@bib29], [@bib30], [@bib42], [@bib46]), but very little is known about the role of PRMT5 in cancer stem cells driving carcinoma formation. In this study, we confirm that PRMT5 regulates the proliferation of bulk breast cancer cells and, more importantly, define a critical role for PRMT5 in the maintenance and propagation of BCSCs *in vitro* and *in vivo* through the epigenetic regulation of FOXP1. These findings are of high clinical relevance because small-molecule inhibitors of PRMT5 are in pre-clinical development, exhibiting good *in vivo* efficacy against lymphomas and leukemia ([@bib8], [@bib29]). Hence, drug targeting PRMT5 in the breast could have a dual effect of not only targeting more differentiated cancer cells but also effectively eliminating the tumor-initiating/BCSC population.

One key observation in this study is that PRMT5 depletion in established tumors, thereby mimicking a patient presenting with disease, substantially decreases BCSC frequency, implying that PRMT5 inhibitors could potentially eradicate this population to prevent relapse. Indeed, our data showing that treatment of patient-derived BCSCs with the tool PRMT5 inhibitor GSK591 decreases BCSC frequency and proliferation represent, to our knowledge, the first account of a PRMT5 inhibitor influencing cancer stem cells derived from solid cancers. One concern with epigenetic-based therapies is that many chromatin remodeling enzymes are essential for normal homeostatic function. Indeed, PRMT5 is an essential gene with deletion causing early embryonic lethality in mice ([@bib42]). Surprisingly, we found that although PRMT5 depletion or inhibition did affect the proliferation of the non-transformed mammary epithelial cell line, MCF10A, self-renewal was unaffected, implying that either PRMT5 is not required for self-renewal of normal mammary stem cells or that residual methyltransferase activity after knockdown or inhibition is sufficient to maintain normal function. Indeed, PRMT5 expression levels are elevated in BCSCs compared with normal mammary stem cells ([Figure 6](#fig6){ref-type="fig"}D), implying that BCSCs are potentially more dependent on PRMT5 activity. Similarly, leukemic CML CD34^+^ cells have elevated PRMT5 expression compared with normal bone marrow CD34^+^ cells, and PRMT5 inhibition only affects the self-renewal of leukemic CD34^+^ stem cells ([@bib29]). Together, our results in conjunction with others imply that elevated PRMT5 expression within cancer stem cells offers a therapeutic window for drug treatment.

We identify that one mechanism by which PRMT5 regulates BCSCs is via the epigenetic regulation of FOXP1. PRMT5 is recruited to the FOXP1 promoter, leading to H3R2me2s, SET1 binding, and H3K4me3. Interestingly, although PRMT5-dependent H3K4me3 is a common mechanism for gene regulation in both leukemic and BCSCs, the genes that are targeted appear to be specific to the origin of the cancer stem cell, implying that the cellular mechanisms by which stemness is maintained by PRMT5 are distinct. Our results clearly show that FOXP1 is an important target of PRMT5, as overexpression can rescue the BCSC proliferation defect induced by GSK591, whereas knockdown decreases BCSC proliferation and self-renewal induced by hyperactive PRMT5. However, depletion of FOXP1 and PRMT5 inhibition are not epistatic for primary and secondary mammosphere formation ([Figure 7](#fig7){ref-type="fig"}B), indicating that although FOXP1 is important, it is not the sole PRMT5 effector. Indeed, given that more than 200 genes are significantly deregulated after PRMT5 depletion, it would be interesting to understand which of these genes are direct epigenetic targets of PRMT5 and which are regulated downstream of FOXP1.

To date, immunohistochemical analysis has suggested that FOXP1 functions as a breast cancer tumor suppressor gene, as low levels correlate with poor prognosis ([@bib44]). In contrast, our findings clearly show that FOXP1 is pro-oncogenic, promoting breast cancer cell proliferation and *in vivo* tumor growth. One reason for the apparent discrepancy is that interpretation of FOXP1 immunohistochemistry is challenging. At least seven isoforms of FOXP1 are expressed, which are all detected by the JC12 antibody ([@bib6]). Given that some isoforms are known to be more oncogenic ([@bib12], [@bib19]) or promote stem cell function ([@bib19]), our results highlight the necessity of understanding the pathological role of a protein before the significance of clinical correlations is made. Indeed, our observations that FOXP1 contributes to BCSC function build upon a growing connection between FOXP1 and normal and cancer stem cell biology ([@bib19], [@bib12], [@bib34]). Interestingly, in ESCs, a switch in FOXP1 isoform usage is responsible for pluripotent gene induction while concurrently repressing differentiation genes ([@bib19]). This is intriguing because PRMT5 is a major regulator of alternative splicing events ([@bib4]). Analysis of *MDM4* splicing failed to detect expression of the splice isoform *MDM4S* ([Figure S6](#mmc1){ref-type="supplementary-material"}C), and our RNA-seq analysis was not at sufficient read depth to detect alterations in splicing patterns, but it would be important to fully explore whether in addition to directly regulating *FOXP1* transcription, PRMT5 might also direct *FOXP1* alternative splicing and isoform use.

In summary, our findings reveal important insights that link arginine methylation to the maintenance of the tumor-initiating BCSC population. Given the development of pre-clinical small molecules targeting PRMT5, combination treatment of PRMT5 inhibitors, along with conventional chemotherapy enabling tumor de-bulking, could have a significant impact on long-term outcomes for breast cancer patients.

Experimental Procedures {#sec4}
=======================

Isolation of Stem Cell-Enriched Populations {#sec4.1}
-------------------------------------------

BCSCs were isolated by either flow cytometry sorting of ESA^+^CD24^low^CD44^+^ MCF7 cells or by isolation of AR cells using the Miltenyi Dead Cell Removal kit. For further details, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Generation of Stable Cell Lines {#sec4.2}
-------------------------------

Cell lines stably expressing shRNA sequences were generated by transducing with lentiviral supernatant containing 8 μg/mL polybrene (Sigma-Aldrich) by centrifugation for 90 min at 4,000 rpm. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more details and shRNA sequences.

Mammosphere Assay {#sec4.3}
-----------------

MCF7, T47D, and MCF10A cells were plated onto pHEMA (Sigma-Aldrich)-coated six-well plates and cultured at 37°C for 5 days. Mammospheres \>50 μm were scored using a graticle. For serial replating, mammospheres were disaggregated and cultured for a further 5 days prior to scoring. For drug treatment, cells were incubated with 5 μM GSK591 or 2.5 μM 4-OHT (Sigma-Aldrich) or vehicle controls. For further details, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Xenograft Studies and *In Vivo* Imaging {#sec4.4}
---------------------------------------

Animal experiments were conducted in accordance with United Kingdom Home Office regulations. For the limiting dilution assay, 5- to 7-week-old female NSG mice were injected with the appropriate number of cells and a slow release estrogen pellet (NE-121; Innovative Research of America) was subcutaneously implanted at the base of the tail. Two hours prior to harvest at the experimental endpoint, mice were injected with 100 mg/kg BrdU (Sigma-Aldrich). For *in vivo* depletion of PRMT5, female NSG mice were injected with 5 × 10^6^ cells and once tumors were palpable, maintained on a diet of dox chow (T-5BQ8-1816629-203; TestDiet). For imaging, mice were injected intraperitoneally (i.p.) with 150 mg/kg of luciferin (Promega), and images were captured on an IVIS Spectrum. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more detail.

RNA Sequencing {#sec4.5}
--------------

Three independent replicates of ESA^+^CD24^low^CD44^+^ cells were isolated by flow cytometry from MCF7 shCTRL or shPRMT5 cells. Total RNA was extracted and rRNA was depleted prior to sequencing on the Illumina Hiseq. Sequenced reads were mapped to build hg19 of the human genome from the University of California, Santa Cruz (UCSC) genome database. Differential gene expression was determined using Cuffdiff 2.2.1 with a threshold of false discovery rate (FDR) \<0.05 and fold change \>1.5. Enriched Gene Ontology terms and KEGG pathways were identified using DAVID (<https://david.ncifcrf.gov>) ([@bib28]). For more detail, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

ChIP {#sec4.6}
----

Chromatin extraction and ChIP were performed as described previously ([@bib13]). Briefly, cells were fixed, lysed, and sonicated to produce DNA fragments of between 300 and 500 bp. Chromatin was precleared and ChIP was performed using chromatin equivalent to 5 × 10^6^ cells. Chromatin was incubated overnight at 4°C with antibody followed by 3 hr incubation with protein G beads. Immunoprecipitated DNA was reverse crosslinked and treated with proteinase-K. DNA was isolated by phenol/chloroform extraction and ethanol precipitation. For ChIP of AR cells, cells were treated for 5 days with 5 μM GSK591 prior to replating overnight in suspension. AR cells were isolated using the Miltenyi Dead Cell Removal kit. Following isolation, cells were processed as above. For more detail, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec4.7}
--------------------

Unless otherwise stated, error bars represent mean ± SEM, n ≥ 3 animals or experimental repeats. All statistical analysis was carried out using Student's t test (^∗^p \< 0.05, ^∗∗^p \< 0.001, ^∗∗∗^ p \< 0.005).

Data and Software Availability {#app1}
==============================

Original scans of all immunoblots presented in this manuscript can be found at <https://data.mendeley.com/datasets/h4y9yxzk3k/draft?a=d426c8ce-edd6-4a3a-9d7f-1e0aac13565a>.

The accession number for the RNA-seq data reported in this paper is GEO: [GSE107762](ncbi-geo:GSE107762){#intref9910}.
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